Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
You may also be interested in...
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.